{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T08:22:11Z","timestamp":1782375731732,"version":"3.54.5"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ijrobp.2022.05.042","type":"journal-article","created":{"date-parts":[[2022,6,5]],"date-time":"2022-06-05T01:15:08Z","timestamp":1654391708000},"page":"977-988","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["A Systematic Review of the Cost-Effectiveness of Stereotactic Radiation Therapy for Cancer Oligometastases"],"prefix":"10.1016","volume":"114","author":[{"given":"Vivek","family":"Verma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Yegya-Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Sprave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Welsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe Y.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven H.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2022.05.042_bib0001","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: Long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.05.042_bib0002","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: Long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.05.042_bib0003","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2022.05.042_bib0004","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ijrobp.2021.09.022","article-title":"appropriate use criteria on radiation therapy in oligometastatic or oligoprogressive non-small cell lung cancer (NSCLC)","volume":"112","author":"Amini","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.05.042_bib0005","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1158\/1055-9965.EPI-19-1534","article-title":"Medical care costs associated with cancer survivorship in the United States","volume":"29","author":"Mariotto","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ijrobp.2022.05.042_bib0006","doi-asserted-by":"crossref","first-page":"166","DOI":"10.21037\/atm.2018.03.28","article-title":"Financial toxicity and implications for cancer care in the era of molecular and immune therapies","volume":"6","author":"Tran","year":"2018","journal-title":"Annal Transl Med"},{"key":"10.1016\/j.ijrobp.2022.05.042_bib0007","first-page":"153","article-title":"The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment","volume":"68","author":"Carrera","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijrobp.2022.05.042_bib0008","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1200\/JCO.2016.68.2518","article-title":"Updating the American Society of Clinical Oncology value framework: Revisions and reflections in response to comments received","volume":"34","author":"Schnipper","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.05.042_bib0009","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int J Surg"},{"key":"10.1016\/j.ijrobp.2022.05.042_bib0010","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ijrobp.2022.05.042_bib0011","doi-asserted-by":"crossref","first-page":"f1049","DOI":"10.1136\/bmj.f1049","article-title":"Consolidated health economic evaluation reporting standards (CHEERS) statement","volume":"346","author":"Husereau","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.ijrobp.2022.05.042_bib0012","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.ijrobp.2016.01.020","article-title":"Cost-effectiveness of surgery, stereotactic body radiation therapy, and systemic therapy for pulmonary oligometastases","volume":"95","author":"Lester-Coll","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.05.042_bib0013","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.radonc.2018.07.017","article-title":"A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC)","volume":"129","author":"Panje","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2022.05.042_bib0014","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/COC.0000000000000608","article-title":"Cost-effectiveness analysis of upfront SBRT for oligometastatic stage IV non-small cell lung cancer based on mutational status","volume":"42","author":"Kim","year":"2019","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.05.042_bib0015","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.ijrobp.2020.06.009","article-title":"Cost-effectiveness of metastasis-directed therapy in oligorecurrent hormone-sensitive prostate cancer","volume":"108","author":"Parikh","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.05.042_bib0016","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/j.clon.2020.08.010","article-title":"Cost-effectiveness analysis of stereotactic ablative body radiation therapy compared with surgery and radiofrequency ablation in two patient cohorts: Metastatic liver cancer and hepatocellular carcinoma","volume":"33","author":"Jin","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2022.05.042_bib0017","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.ijrobp.2020.12.001","article-title":"Is SABR cost-effective in oligometastatic cancer? An economic analysis of the SABR-COMET randomized trial","volume":"109","author":"Qu","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.05.042_bib0018","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.ijrobp.2020.09.045","article-title":"Cost-effectiveness analysis of stereotactic ablative radiation therapy in patients with oligometastatic cancer","volume":"109","author":"Kumar","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.05.042_bib0019","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.3390\/curroncol28030172","article-title":"Cost-effectiveness analysis of stereotactic ablative body radiotherapy for the treatment of oligometastatic tumors versus standard of care","volume":"28","author":"Raymakers","year":"2021","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ijrobp.2022.05.042_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.667993","article-title":"Cost-effectiveness analysis of local treatment in oligometastatic disease","volume":"11","author":"Mehrens","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2022.05.042_bib0021","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1002\/cncr.29882","article-title":"A systematic review of the cost and costeffectiveness studies of proton radiotherapy","volume":"122","author":"Verma","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2022.05.042_bib0022","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.ijrobp.2015.12.359","article-title":"Evaluation of health economics in radiation oncology: A systematic review","volume":"94","author":"Nguyen","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.05.042_bib0023","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jval.2012.04.012","article-title":"Model transparency and validation: A report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7","volume":"15","author":"Eddy","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.ijrobp.2022.05.042_bib0027","doi-asserted-by":"crossref","unstructured":"Wang XS, Bai YF, Verma V, et al. Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated NSCLC [e-pub ahead of print]. J Natl Cancer Inst. http:\/\/doi.org\/10.1093\/jnci\/djac015, accessed January 30, 2022.","DOI":"10.1093\/jnci\/djac015"},{"key":"10.1016\/j.ijrobp.2022.05.042_bib0028","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s40425-018-0442-7","article-title":"A systematic review of the cost and costeffectiveness studies of immune checkpoint inhibitors","volume":"6","author":"Verma","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ijrobp.2022.05.042_bib0029","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1002\/cncr.28814","article-title":"The development of a financial toxicity patient-reported outcome in cancer: The COST measure","volume":"120","author":"De Souza","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2022.05.042_bib0030","doi-asserted-by":"crossref","unstructured":"Kim H, Venkatesulu BP, McMillan MT, et al. Local therapy for oligoprogressive disease: A systematic review of prospective trials [e-pub ahead of print]. Int J Radiat Oncol Biol Phys. http:\/\/doi.org\/10.1016\/j.ijrobp.2022.08.027, accessed August 22, 2022.","DOI":"10.1016\/j.ijrobp.2022.08.027"},{"key":"10.1016\/j.ijrobp.2022.05.042_bib0031","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/jnci\/djx208","article-title":"Quality of life and patient-reported outcomes following proton radiation therapy: A systematic review","author":"Verma","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2022.05.042_bib0032","doi-asserted-by":"crossref","DOI":"10.1097\/01.mlr.0000170001.10393.b7","article-title":"Common methodological flaws in economic evaluations","volume":"43","author":"Drummond","year":"2005","journal-title":"Med Care"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301622005491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301622005491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T10:04:21Z","timestamp":1759745061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301622005491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0360301622005491"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2022.05.042","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Systematic Review of the Cost-Effectiveness of Stereotactic Radiation Therapy for Cancer Oligometastases","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2022.05.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}